BACKGROUND: HPV is important in a subset of HNSCC. Our meta-analysis determined the clinical characteristics of HPV-related HNSCC. METHOD: Pubmed search terms "HPV" and "HNSCC" were used to identify 34 studies since 1980. We obtained pooled adjusted odds ratio (OR) or hazard ratio (HR) using random or fixed-effects model and compared OS depicted in forest plot. RESULTS: A total of 5681 patients were included. The prevalence of HPV+ tumors was 22%, with 86.7% of HPV16+ genotype. The OR for HNSCC in HPV16+ patients was 4.44 (95% CI = 2.87-6.02). HPV status was associated with p16 expression (adj OR = 3.00; 0.90-9.70), and HPV+ tumors were less likely to harbor p53 mutations (adj OR = 0.21; 0.04-0.38). The HR for death in HPV+ patients was 0.42 (0.27-0.57). HPV+ HNSCC also had a better response to therapy. CONCLUSION: HPV+ HNSCC are established as a separate biologic entity. Prospective trials are needed to establish the optimal therapy for HPV+ HNSCC.
BACKGROUND:HPV is important in a subset of HNSCC. Our meta-analysis determined the clinical characteristics of HPV-related HNSCC. METHOD: Pubmed search terms "HPV" and "HNSCC" were used to identify 34 studies since 1980. We obtained pooled adjusted odds ratio (OR) or hazard ratio (HR) using random or fixed-effects model and compared OS depicted in forest plot. RESULTS: A total of 5681 patients were included. The prevalence of HPV+ tumors was 22%, with 86.7% of HPV16+ genotype. The OR for HNSCC in HPV16+ patients was 4.44 (95% CI = 2.87-6.02). HPV status was associated with p16 expression (adj OR = 3.00; 0.90-9.70), and HPV+ tumors were less likely to harbor p53 mutations (adj OR = 0.21; 0.04-0.38). The HR for death in HPV+ patients was 0.42 (0.27-0.57). HPV+ HNSCC also had a better response to therapy. CONCLUSION:HPV+ HNSCC are established as a separate biologic entity. Prospective trials are needed to establish the optimal therapy for HPV+ HNSCC.
Authors: Lalle Hammarstedt; David Lindquist; Hanna Dahlstrand; Mircea Romanitan; Liselotte Onelöv Dahlgren; Jeanna Joneberg; Nomi Creson; Johan Lindholm; Weimin Ye; Tina Dalianis; Eva Munck-Wikland Journal: Int J Cancer Date: 2006-12-01 Impact factor: 7.396
Authors: Paul M Weinberger; Ziwei Yu; Bruce G Haffty; Diane Kowalski; Malini Harigopal; Janet Brandsma; Clarence Sasaki; John Joe; Robert L Camp; David L Rimm; Amanda Psyrri Journal: J Clin Oncol Date: 2006-01-09 Impact factor: 44.544
Authors: Niklas Reimers; Hans U Kasper; Soenke J Weissenborn; Hartmut Stützer; Simon F Preuss; Thomas K Hoffmann; Ernst Jan M Speel; Hans P Dienes; Herbert J Pfister; Orlando Guntinas-Lichius; Jens P Klussmann Journal: Int J Cancer Date: 2007-04-15 Impact factor: 7.396
Authors: Olcay Cem Bulut; Katja Lindel; Henrik Hauswald; Regine Brandt; Frederick Klauschen; Janina Wolf; Thomas Wolf; Peter K Plinkert; Christian Simon; Wilko Weichert; Albrecht Stenzinger Journal: Eur Arch Otorhinolaryngol Date: 2013-08-29 Impact factor: 2.503
Authors: Josena K Stephen; Kang Mei Chen; Veena Shah; Shaleta Havard; Mei Lu; Vanessa P Schweitzer; Glendon Gardner; Maria J Worsham Journal: Otolaryngol Head Neck Surg Date: 2012-01-20 Impact factor: 3.497
Authors: Christian Jacobi; Josepha Rauch; Jan Hagemann; Thomas Lautz; Maximilian Reiter; Philipp Baumeister Journal: Eur Arch Otorhinolaryngol Date: 2017-12-04 Impact factor: 2.503
Authors: James S Lewis; William H Westra; Lester D R Thompson; Leon Barnes; Antonio Cardesa; Jennifer L Hunt; Michelle D Williams; Pieter J Slootweg; Asterios Triantafyllou; Julia A Woolgar; Kenneth O Devaney; Alessandra Rinaldo; Alfio Ferlito Journal: Head Neck Pathol Date: 2013-12-14
Authors: Moonef Alotaibi; Valeria Valova; Toni HÄnsel; Carmen Stromberger; Grzegorz Kofla; Heidi Olze; Iris Piwonski; Andreas Albers; Sebastian Ochsenreither; Annekatrin Coordes Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: B Pajares; L Perez-Villa; J M Trigo; M D Toledo; M Alvarez; B Jimenez; J A Medina; V de Luque; J M Jerez; E Alba Journal: Clin Transl Oncol Date: 2013-11-06 Impact factor: 3.405